ASH Annual Meeting & Exposition: Multiple Myeloma

Adding isatuximab to lenalidomide, bortezomib, and dexamethasone demonstrated a superior minimal residual disease rate in patients with transplant-eligible newly diagnosed multiple myeloma.

The combination of daratumumab with bortezomib, cyclophosphamide, and dexamethasone continued to improve hematologic and organ responses after 18 months of follow-up.

Findings from the phase 1b TRIMM-2 study indicated that patients with relapsed/refractory multiple myeloma experienced manageable toxicities and promising responses to treatment with talquetamab and daratumumab.

Research presented at the 63rd ASH Annual Meeting and Exposition found significantly higher MRD-negativity and sustained MRD-negativity rates among patients with transplant-eligible newly diagnosed multiple myeloma receiving D-VTd over VTd alone.

Patients with newly diagnosed multiple myeloma who are non-transplant eligible and intermediate-fit and who received a less toxic regimen of ixazomib, daratumumab, and low-dose dexamethasone demonstrated higher rates of objective response.

A phase 2 trial shows promise of the daratumumab/ixazomib combination in frail and elderly patients with multiple myeloma who are treated in the relapsed setting when given without dexamethasone.

Patients receiving daratumumab, lenalidomide, and dexamethasone in the first line saw better overall survival than those who waited and received second-line daratumumab-based regimens for transplant-ineligible newly diagnosed multiple myeloma.

Thomas G. Martin, MD, spoke about different abstracts to be presented at ASH 2021.

The expert in multiple myeloma highlighted the research which she was most excited to see presented at the ASH Annual Meeting & Exposition.

Hypogammaglobulinemia was found to be nearly universal for patients with multiple myeloma during treatment with daratumumab, suggesting a role for intravenous immunoglobulin.

The director of clinical research in the Center for Cancer Care at White Plains Hospital spoke about what she intends to evaluate for a patient population with multiple myeloma and diabetes moving forward.

Jeffrey Wolf, MD, explained how studies presented at the recent 2020 ASH Annual Meeting & Exposition did not report what percentage of patients achieved minimal residual disease negativity with therapy for multiple myeloma, and that the future of phase 3 trials should focus on this status in patients.

The ongoing phase 1/2 DREAMM-6 trial found that the addition of belantamab mafodotin to bortezomib and dexamethasone elicited high response rates and a suitable safety profile in patients with relapsed or refractory multiple myeloma.

Daratumumab plus lenalidomide, bortezomib, and dexamethasone improved response rates and depth of response in patients with transplant-eligible, newly diagnosed multiple myeloma.

TNB-383B was well tolerated and researchers saw significant responses when it was administered at a higher dose level for heavily pretreated patients with relapsed/refractory multiple myeloma.

Data presented at the 2020 ASH Meeting found talquetamab elicited a high response rate with a tolerable safety profile for patients with relapsed/refractory multiple myeloma.

The myeloma expert discussed the randomized, open label study measuring the safety and efficacy of daratumumab (Darzalex) plus RVd for patients with newly diagnosed multiple myeloma.

Cevostamab, a FcRH5xCD3 bispecific antibody, was safe and highly active when treating heavily pretreated patients with relapsed/refractory multiple myeloma, according to data presented at the 2020 ASH Annual Meeting & Exposition.

The BCMA- and CD3-targeted bispecific monoclonal antibody, demonstrated early, deep, and durable responses with acceptable safety and tolerability in patients with relapsed/refractory multiple myeloma.

The combination induced low rates of infusion-related reaction, and had a shorter administration duration, increasing convenience for patients and decreasing treatment burden, according to Meletios A. Dimopoulos, MD.

The enriched chimeric antigen receptor T-cell therapy improved responses and prolonged duration of response in patients with relapsed/refractory multiple myeloma.

CC-93269 showed encouraging signs of dose-dependent efficacy with a safety profile that continues to be refined for patients with heavily pretreated relapsed/refractory multiple myeloma.

Chimeric antigen receptor T-cell therapy targeting both BCMA and CD38 induced an objective response in >90% of patients with multiple myeloma who had been treated with at least 3 prior therapies and whose disease had spread outside of the bone marrow.

Researchers examined adding daratumumab to standard of care in newly diagnosed transplant-ineligible myeloma patients.

Researchers uncovered distinct clinical characteristics in relapsed/refractory multiple myeloma patients receiving proteasome inhibitors.

Researchers analyzed double vs single autologous stem cell transplantation in patients with newly diagnosed multiple myeloma, after previous conflicting results.

This study looked at the benefit of early therapeutic intervention with the combination of elotuzumab, lenalidomide, and dexamethasone in patients with high-risk smoldering multiple myeloma.

An investigational antibody-drug conjugate that targets a key B-cell maturation antigen, offers “deep and durable” responses to some patients with relapsed/refractory multiple myeloma, suggest preliminary findings from the expansion part of the phase I DREAMM-1 trial.

Adding daratumumab to either of two standard-of-care treatment regimens induces rapid, deep, and durable responses and improves progression-free survival in patients with relapsed/refractory multiple myeloma, confirm updated findings from the open-label phase III POLLUX and CASTOR trials.

A single treatment with a second-generation CAR T-cell treatment elicited an overall response rate of 94% in a small study of patients with heavily pretreated multiple myeloma, according to the results of a phase I study presented at the ASH Annual Meeting.